Exhibit 10.23
NEUMORA THERAPEUTICS, INC.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
This Amended and Restated Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Carol Y. Suh (“Executive” and, together with the Company, the “Parties”) effective as of January 1, 2023 (the “Effective Date”). This Agreement supersedes in its entirety that certain Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).
WHEREAS, the Company desires to assure itself of the continued services of Executive by engaging Executive to perform services as an employee of the Company under the terms hereof;
WHEREAS, Executive desires to provide continued services to the Company on the terms herein provided; and
WHEREAS, the Parties desire to execute this Agreement to supersede the Prior Agreement in its entirety effective as of the Effective Date.
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
[Signature Page Follows]
IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date and year first above written.
NEUMORA THERAPEUTICS, INC.
By: /s/ Henry Gosebruch
Name: Henry Gosebruch
Title: Chief Executive Officer
EXECUTIVE
By: /s/ Carol Y. Suh
Name: Carol Y. Suh
Exhibit A
PERMITTED OUTSIDE ACTIVITIES